scholarly journals 680 Peripheral intravascular lithotripsy of ILEO-femoral arteries to facilitate transfemoral TAVI: a multicentric prospective registry

2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Giulia Nardi ◽  
Ole De Backer ◽  
Francesco Saia ◽  
Lars Sondergaard ◽  
Francesca Ristalli ◽  
...  

Abstract Aims The presence of severe calcific atherosclerosis at the iliofemoral axis may preclude transcatheter aortic valve implantation (TAVI) by transfemoral (TF) approach. Intravascular lithotripsy (IVL) is a novel technology that fractures intimal/medial calcium and increases vessel compliance allowing TF-TAVI in selected patients with peripheral artery disease (PAD). To report on the safety and efficacy of IVL-assisted TF-TAVI in an all-comers population. Methods and results Clinical, imaging and procedural data on all consecutive patients treated by IVL-assisted TF-TAVI in six high-volume European centres (2018–2020) were collected in this prospective, real-world, multicentre registry. IVL-assisted TF-TAVI was performed in 108 patients, increasing from 2.4% to 6.5% of all TAVI in 2018 to 2020, respectively. The target lesion was most often localized at the common and/or external iliac artery (93.5% of cases; average TL-MLD 4.6 ± 0.9 mm with 318 degrees of calcium arc). Transfemoral aortic valve delivery was successful in 100% of cases; final procedural success in 98.2% (two conversion to cardiac open surgery for annular rupture and valve migration). Complications of the IVL-treated segments consisted of one perforation and three major dissections requiring stent implantation (two covered stents and two BMS). Access site related complication included three major bleedings. Three in-hospital deaths were recorded (2.8%, one failed surgical conversion after annular rupture, one cardiac arrest after initial valvuloplasty, one late hyperkalaemia in renal dysfunction). Conclusions IVL-assisted TF-TAVI proved to be a safe and effective approach, which helps expanding the indications for TF-TAVI in patients with severe calcific PAD. Still, these patients maintain a higher than average incidence of peri-procedural complication.

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Majid Ahsan ◽  
Rolf Alexander Jánosi ◽  
Tienush Rassaf ◽  
Alexander Lind

Abstract Background Patients with severe aortic stenosis (AS) often present with multiple comorbidities and suffer from critical coronary artery disease (CAD). Transcatheter aortic valve replacement (TAVR) has become the therapy of choice for moderate to high-risk patients. Venoarterial extracorporeal membrane oxygenation (v-a-ECMO) offers the possibility of temporary cardiac support to manage life-threatening critical situations. Case summary Here, we describe the management of a patient with severe AS and CAD with impaired left ventricular ejection fraction (LVEF). We used v-a-ECMO as an emergency strategy in cardiogenic shock during a high-risk coronary intervention to stabilize the patient, and as a further bridge to TAVR. Discussion Very high-risk patients with severe AS are unlikely to tolerate the added risk of surgical aortic valve replacement. Using ECMO may help them to benefit from TAVR as the only treatment option available.


Circulation ◽  
2018 ◽  
Vol 138 (Suppl_1) ◽  
Author(s):  
Nidal Ganim ◽  
Dominique J Monlezun ◽  
Enrique D Garcia-Sayan ◽  
Prakash Balan

Background: Transcatheter aortic valve replacement (TAVR) has ample randomized trial evidence that it can reduce mortality and cost for patients with aortic stenosis. Yet racial disparities in procedure access are poorly understood. Methods: This case-control prospectively enrolled TAVR subjects at a single high-volume quaternary academic medical center in Houston, Texas, USA, from 11/8/11-3/28/18. Neural network machine learning-supported binomial probability testing was conducted comparing the Houston population versus the center’s TAVR rates by race, with mortality and cost extrapolations. The IOM definition of health inequities was applied using the rank and replace method for counterfactual comparison (matching subjects by insurance and Society of Thoracic Surgery [STS] risk score for TAVR eligibility). Results: Compared to the Houston population, TAVR subjects (N=1641) were significantly more likely to be Caucasians (51.93% vs 77.26%), and less likely to be African Americans (14.80% vs 6.02%), Hispanics (23.63% vs 15.02%), or other races (9.50% vs 1.70%), all p<0.001. Among TAVR subjects with private insurance, the large majority were Caucasian (832, 85.60%), with the minority being African American (34, 3.50%), Hispanic (96, 9.88%), and other (10, 37.04%) (private insurance by Caucasian versus non-Caucasian, p<0.001). Based on TAVR mortality and cost savings in the PARNTER trial, access disparities for racial minorities over 5 years may result in 858 excess deaths, $130,000 per patient excess costs, and $111.5 million excess costs per the overall sample of eligible presenting Houston subjects. The predicted versus actual racial distribution of TAVR for each minority group matched to Caucasians by insurance and STS score was significantly greater than the actual (each group comparison to Caucasians, p<0.001). Conclusion: Multi-year data from our high-volume center suggest Houston racial minorities are less likely to undergo TAVR, potentially translating into a growing number of preventable excess early deaths and costs as disease incidence increases. Additional studies are underway to determine and reduce the degree of preventable race-related disparities independent of known access predictors.


Sign in / Sign up

Export Citation Format

Share Document